U.S
Intravenous Solution Market, by Solution Type (Saline (Normal saline 0.9%
NaCl and Hypertonic saline), Dextran (D5W 5% dextrose in water and Analog
Hypertonic Saline), Lactated Ringer’s, Amino Acid, Vitamins & Minerals,
Heparin and trace elements, and Mixed Solutions), By Packaging (Ampules, Vials,
Cartridges, Bottles, Bags (Large Volume Bags-greater than 250ml and Small
Volume Bags-less than 250ml), By Indication (Oncology, Post-Operative Care,
General Medicine, Burn Management, Pulmonary Disorders, Cardiovascular
Diseases, and Others), and By End User (Hospitals, Clinics, Ambulatory Surgical
Centers, Home care Settings, and Others) is estimated to be valued at US$
2,811.3 million in 2021 and is expected to exhibit a CAGR of 6.1% during the
forecast period (2021-2028), as highlighted in a new report published by
Coherent Market Insights.
U.S Intravenous Solutions Market-
Impact of Coronavirus (COVID-19) Pandemic
Lockdown in various countries due
to the pandemic has placed an economic burden on the private healthcare sector.
Healthcare providers are facing challenges with regards to declining
outpatient’s visits, manpower, equipment, consumables, and other resources to
ensure safety in treatment of patients with other diseases. The global COVID-19
pandemic has sharply focused the attention of the world onto critical care of
COVID-19 patients. During the early stages of the COVID-19 pandemic, it was a
common advice of physicians to aim for a negative fluid balance. Nowadays, a
higher occurrence of acute kidney injury requiring renal replacement therapy
has been observed, prompting for a more liberal fluid strategy. For instance,
the World Health Organization guidelines recommend that patients with COVID-19
in respiratory failure should be treated cautiously with intravenous fluids,
especially in settings with limited availability of mechanical ventilation.
Use a conservative fluid
management strategy for acute respiratory distress syndrome (ARDS) patients
without tissue hypoperfusion
In resuscitation for septic shock
in adults, give 250–500 mL crystalloid fluid as a rapid bolus in the first
15–30 minutes and reassess for signs of fluid overload after each bolus
Consider dynamic indices of
volume responsiveness to guide volume administration beyond initial
resuscitation based on local resources and experience. These indices include
passive leg raises, fluid challenges with serial stroke volume measurements, or
variations in systolic pressure, pulse pressure, inferior vena cava size, or
stroke volume in response to changes in intrathoracic pressure during
mechanical ventilation.
Thus, due to lockdown and
disruption in supply chain and the increasing demand of healthcare products for
patients, this pandemic has hampered the U.S intravenous solution market.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/3400
However, the increasing number of
product approvals from regulatory bodies, collaborations and partnership
strategies adopted by key players are some of the major factors which are
expected to drive growth of the U.S intravenous solution market during the
forecast period. For instance, in November 2016, Mallinckrodt Pharmaceuticals
received U.S. Food and Drug Administration’s (FDA) Prior Approval Supplement
for its OFIRMEV (acetaminophen) injection (new drug application) available in
an intravenous (IV) bag presentation.
Administration of IV fluids in
the patients of cardiac arrhythmia helps in improvement of haemodynamic status
in critically ill patients. Thus, the increasing number prevalence of cardiac
arrhythmia is expected to provide huge opportunities to the U.S intravenous
solution market growth in the near future. For instance, the Centers for
Disease Control and Prevention 2014, estimated that 2.7–6.1 million people in
the U.S. suffered from atrial fibrillation. With increasing aging population,
this number is also expected to increase.
The increasing number of patient
admissions in ambulatory surgical centers for surgical procedures, which
requires intravenous solutions or infusion for administration of drugs is
expected to drive the ambulatory surgical centers (ASCs) segment growth. For
instance, according to the H-Cup Journal Report 2017, in the U.S., there were
around 17.2 million ambulatory hospital visits recorded in the hospitals.
A person suffering from diarrhea
also suffers from intense fluid loss and dehydration. Thus, diarrhea patients
are highly prescribed with IV fluids such as saline and vitamins. Increasing
prevalence of diarrhea is expected to drive growth of U.S intravenous solution
market during the forecast period. For instance, according to the article
published in New England Journal of Medicine, April 2014, 179 million cases of
acute diarrhea are registered annually in the U.S.
Browse 13 Market Data Tables and
40 Figures spread through 169 Pages and in-depth TOC on U.S Intravenous
Solution Market, by Solution Type (Saline (Normal saline 0.9% NaCl and
Hypertonic saline), Dextran (D5W 5% dextrose in water and Analog Hypertonic
Saline), Lactated Ringer’s, Amino Acid, Vitamins & Minerals, Heparin and
trace elements, and Mixed Solutions), By Packaging (Ampules, Vials, Cartridges,
Bottles, Bags (Large Volume Bags-greater than 250ml and Small Volume Bags-less
than 250ml), By Indication (Oncology, Post-Operative Care, General Medicine,
Burn Management, Pulmonary Disorders, Cardiovascular Diseases, and Others), and
By End User (Hospitals, Clinics, Ambulatory Surgical Centers, Home care
Settings, and Others) - Forecast to 2028"
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/us-intravenous-solution-market-3400
The increasing number of
surgeries are expected to propel demand for large volume of Intravenous (IV)
solutions. For instance, according to Healthcare Cost and Utilization Project
report 2020, a total of 17.2 million hospital visits (as visits or inpatient
stays) in the United States included at least one surgery in 2017.
Key Takeaways of the U.S
Intravenous Solution Market:
The U.S intravenous solution
market is expected to exhibit a CAGR of 6.1% during the forecast period
(2021-2028) owing to the increasing launches of new intravenous solution
injections for the treatment of various issues such as neuromuscular blockade
and paralysis, this is expected to boost the market growth over the forecast
period. For instance, in 2017, Fresenius Kabi USA, LLC, a provider of medicines
and technologies for infusion, transfusion, and clinical nutrition, launched
Vecuronium Bromide IV injection in the U.S. The drug is indicated for
maintenance of neuromuscular blockade and paralysis.
Among solution type, Saline
segment is expected to hold major revenue share in 2028, owing to the
increasing incidence of gastroenteritis, which is expected to contribute to the
growth of the saline segment. For instance, according to the data of National
Center of Biotechnology Information 2020, acute viral gastroenteritis accounts
for 19 to 21 million cases of diarrheal illnesses annually in the U.S.
Major players operating in the
U.S intravenous solution market are B. Braun Melsungen AG., Baxter
International Inc., Fresenius Kabi USA, LLC, Grifols, S.A., JW Life Science,
Amanta Healthcare, Salius Pharma Private Limited, Axa Parenterals Ltd., Vifor
Pharma Management Ltd., ICU Medical, Inc., and Pfizer Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/3400
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200 Seattle,
WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment